Ask AI

Bridging Breast Cancer Discoveries to Practice—CCO's Independent Conference Highlights From the 2025 ESMO Breast Congress *

Gain expert insights into the latest on oral SERDs in clinical practice for the management of ER+/HER2- breast cancer, factors that affect decision-making, and future directions with combination therapies based on the most recent evidence presented at key conferences through a certified ClinicalThought commentary.

Share

Program Content

Activities

Oral SERDs A Step Forward
Oral SERDs in HR+/HER2- Breast Cancer: A Step Forward in Precision Endocrine Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 17, 2025

Expires: May 16, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.